Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;2012:809614.
doi: 10.1155/2012/809614. Epub 2011 Dec 10.

Spore Powder of Ganoderma Lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial

Affiliations
Free PMC article

Spore Powder of Ganoderma Lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial

Hong Zhao et al. Evid Based Complement Alternat Med. .
Free PMC article

Abstract

The fatigue prevalence in breast cancer survivors is high during the endocrine treatment. However, there are few evidence-based interventions to manage this symptom. The aim of this study was to investigate the effectiveness of spore powder of Ganoderma lucidum for cancer-related fatigue in breast cancer patients undergoing endocrine therapy. Spore powder of Ganoderma lucidum is a kind of Basidiomycete which is a widely used traditional medicine in China. 48 breast cancer patients with cancer-related fatigue undergoing endocrine therapy were randomized into the experimental or control group. FACT-F, HADS, and EORTC QLQ-C30 questionnaires data were collected at baseline and 4 weeks after treatment. The concentrations of TNF-α, IL-6, and liver-kidney functions were measured before and after intervention. The experimental group showed statistically significant improvements in the domains of physical well-being and fatigue subscale after intervention. These patients also reported less anxiety and depression and better quality of life. Immune markers of CRF were significantly lower and no serious adverse effects occurred during the study. This pilot study suggests that spore powder of Ganoderma lucidum may have beneficial effects on cancer-related fatigue and quality of life in breast cancer patients undergoing endocrine therapy without any significant adverse effect.

Figures

Figure 1
Figure 1
The concentrations of TNF-α in experimental group and control group at baseline and 4 week.
Figure 2
Figure 2
The concentrations of IL-6 in experimental group and control group at baseline and 4 week.

Similar articles

See all similar articles

Cited by 15 articles

See all "Cited by" articles

References

    1. Eustachi A. Complementary therapies in breast cancer patients. Breast Care. 2007;2(4):209–216.
    1. Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Research and Treatment. 1996;39(3):261–273. - PubMed
    1. Eaker S, Wigertz A, Lambert PC, Bergkvist L, Ahlgren J, Lambe M. Breast cancer, sickness absence, income and marital status: a study on life situation 1 year prior diagnosis compared to 3 and 5 years after diagnosis. PLoS ONE. 2011;6(3) Article ID e18040. - PMC - PubMed
    1. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors—a longitudinal investigation. Cancer. 2006;106(4):751–758. - PubMed
    1. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. The Lancet. 2003;362(9384):640–650. - PubMed
Feedback